This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hyperion Therapeutics Announces RAVICTI And BUPHENYL Pharmacokinetic Analyses Reported In The Journal Of Clinical Pharmacology

SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that population pharmacokinetic (PK) modeling and dosing simulations were reported in The Journal of Clinical Pharmacology based on data from four Phase 2 and 3 trials that collectively enrolled patients with urea cycle disorders (UCDs) ages 2 months to 72 years. The final model described the differences in absorption rate and pharmacokinetic profiles of the company's two drugs, RAVICTI® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, in patients with UCDs. The article is available through the Wiley online library ( http://onlinelibrary.wiley.com/doi/10.1002/jcph.92/abstract ).

UCDs represent a collection of inherited enzyme and transporter deficiencies that impair the synthesis of urea, the body's vehicle for waste nitrogen removal via the urine, which results in affected patients suffering from high systemic levels of ammonia, a potent neurotoxin. Since UCDs constitute an ultra-orphan population with an estimated U.S. patient pool of approximately 1000, population PK modeling and dosing simulations were performed to help define the clinical pharmacology of the two compounds as well as metabolite exposure in pediatric and adult UCD patients.

The final model helps explain differences in the level of plasma metabolites (drug breakdown products) during dosing of the two drugs based on differences in the amount of drug metabolized to phenylacetylglutamine prior to reaching the systemic circulation. Moreover, during dosing with RAVICTI as compared with BUPHENYL, phenylbutyric acid is absorbed 70-75% more slowly and blood metabolite levels generally show less fluctuation.

"These modeling data are particularly interesting in that the slower input of the active ingredient into the circulation with RAVICTI as compared with the bolus type drug release of BUPHENYL may allow for more sustained ammonia control," said Dr. George Diaz, Associate Professor, Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs